NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.08 USD
-0.01 (-9.97%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.08 0.00 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
NovaBay Pharmaceuticals, Inc. [NBY]
Reports for Purchase
Showing records 101 - 109 ( 109 total )
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transferring Coverage; Rating, PT and Estimates Under Review
Provider: Roth Capital Partners, Inc.
Analyst: MARTIN J
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Business Update Suggests Potential Pipeline Acceleration - Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: MOSKOWITZ D
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and our 12-month target price of $4.25
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and maintain our price target of $9.00.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and our target price of $9.00 per share
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K